Oramed Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on August 29, 2019, and September 5, 2019. Oramed Pharmaceuticals Inc. is a Delaware corporation with principal executive offices in New York, New York. The company's common stock trades on The Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses on corporate governance and a new financing arrangement.
Material Changes and Agreements
- Equity Distribution Agreement: On September 5, 2019, the Company entered into an agreement with Canaccord Genuity LLC to sell up to $15 million of common stock via an "at-the-market" offering. Canaccord Genuity will receive a 3.0% cash commission on gross proceeds. The Company is not obligated to sell any shares, and the agreement may be terminated by either party with five days' notice.
- Stock Incentive Plan Approval: At the 2019 Annual Meeting on August 29, 2019, stockholders approved the 2019 Stock Incentive Plan, which allows for awards to officers and directors.
Corporate Governance and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Re-election of Directors: All six nominees (Miriam Kidron, Nadav Kidron, Aviad Friedman, Kevin Rakin, Leonard Sank, and Gao Xiaoming) were re-elected. Votes ranged from approximately 4.23 million to 4.40 million "For" votes.
- 2019 Stock Incentive Plan: Approved with 3,743,648 votes "For" and 598,388 votes "Against."
- Ratification of Auditors: Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) was ratified with 9,904,624 votes "For" and 92,925 votes "Against."
Outlook, Risks, and Contingencies
The filing notes that no assurance can be given regarding the price, amount, or timing of any future share sales under the Equity Distribution Agreement. The agreement is subject to customary termination rights and indemnification provisions.
Key Facts for Investor Verification
- Verify the current cash position and burn rate to assess the necessity of the $15 million equity distribution facility.
- Review the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific pricing parameters and termination clauses.
- Monitor future 8-K filings for actual sales of shares under the new agreement and the resulting dilution impact.
- Confirm the number of shares reserved under the newly approved 2019 Stock Incentive Plan in the referenced Proxy Statement.